Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy (2023)
Attributed to:
Developing a decision support tool to enable precision treatment of type 2 diabetes
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s12933-023-02032-x
PubMed Identifier: 37919773
Publication URI: http://europepmc.org/abstract/MED/37919773
Type: Journal Article/Review
Parent Publication: Cardiovascular Diabetology
Issue: 1
ISSN: 1475-2840